Forte Biosciences Inc (FBRX)

NasdaqCM · Biotechnology

76.99
+0.00 (+0.00%)
Updated Nov 16, 3:42 AM ET
AI Rating
Buy
Overall Score
74
Trend
100
Momentum
30
Risk
92

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Aug 18, 2025 260 sessions Aug 28, 2026

AI Analysis

Forte Biosciences Inc is trading at $76.99, up 0.00% on the session. The 50 day average sits at $55.12 and the 200 day at $32.86, which puts the stock in a uptrend. RSI is at 84.4, which reads as overbought, and MACD is bearish crossover. Volume is below average.

The nearest support is around $76.82 with resistance near $77.20, so that band frames the current range. Average daily movement is roughly $1.08, or about 1.4% of the share price, which is what any stop placement has to allow for. The overall health score of 74 out of 100 combines a trend score of 100, momentum of 30 and a risk score of 92.

Technical indicators

RSI (14)
84.4
overbought
MACD
5.295
bearish crossover
SMA 20
76.85
SMA 50
55.12
SMA 200
32.86
uptrend
ATR (14)
1.08
avg daily range
Support
76.82
Resistance
77.20
Volume vs 20d
--
below average
Volatility
1.3%
annualised
1 month
+0.01%
3 months
+303.94%

About Forte Biosciences Inc

Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.